| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Utilizing human kidney 293T cells, the inhibitory effect of ginsenoside Rb3 (0.1–10 μM) is tested on the nuclear factor kappa–light chain enhancer–induced activity of activated B cell (NF-κB) luciferase reporter gene. Measurement of effects. Ginsenoside Rb3 exhibited noteworthy activity, demonstrating an IC50 of 8.2 μM. Following treatment of HepG2 cells with TNF-α (10 ng/mL) route (mRNA) induction, ginsenoside Rb3 also inhibited cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) messenger ribose in a dose-dependent manner [1]. In a dose-dependent manner, ginsenoside Rb3 (0.1–10 μM) dramatically enhanced cell survival and prevented the release of kinase dehydrogenase (LDH). The viability of PC12 cells as determined by MTT decrease was found to be considerably lower following exposure to oxygen and increased glucose (OGD)/OGD-Rep. On the other hand, pretreatment of cells with 0.1, 1, and 10 μM of ginsenoside Rb3 dramatically disturbed the cytotoxicity generated by OGD/OGD-Rep, and this toxicity was reduced in a concentration-dependent way. In contrast to sensors, the death rate rose to 52.8%±5.6%, 64.6%±5.7%, and 76.4%±8.8%, in that order[2].
|
|---|---|
| ln Vivo |
The primary compound identified from Gynostemma pentaphyllum is ginsenoside Rb3, which has the ability to significantly enhance the contaminated microenvironment and cause anti-polyposis in ApcMin/+ mice. Ginsenoside Rb3 was administered to mice treated at six weeks of age prior to the development of intestinal polyps. Changes in the mice's body weight, water and food intake were tracked. Throughout the trial, no Rb3/Rd-related weight gain in mice was seen. Furthermore, there were no differences in food or water consumption among the treated rats. However, ginsenoside Rb3 therapy effectively decreased the size and quantity of polyps [3].
|
| References |
|
| Additional Infomation |
Ginsenoside Rb3 is a ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 3 and 20 have been converted to the corresponding beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranoside and beta-D-xylopyranosyl-(1->6)-beta-D-glucopyranoside respectively, and in which a double bond has been introduced at the 24-25 position. It has a role as a plant metabolite, an antioxidant, an antidepressant, a cardioprotective agent, a NMDA receptor antagonist and a neuroprotective agent. It is a 12beta-hydroxy steroid, a beta-D-glucoside, a disaccharide derivative, a ginsenoside and a tetracyclic triterpenoid. It derives from a hydride of a dammarane.
Gypenoside IV has been reported in Panax japonicus and Gynostemma pentaphyllum with data available. |
| Molecular Formula |
C53H90O22
|
|---|---|
| Molecular Weight |
1079.28
|
| Exact Mass |
1078.592
|
| CAS # |
68406-26-8
|
| PubChem CID |
12912363
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1117.1±65.0 °C at 760 mmHg
|
| Flash Point |
629.4±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.622
|
| LogP |
4.73
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
75
|
| Complexity |
1950
|
| Defined Atom Stereocenter Count |
29
|
| InChi Key |
NODILNFGTFIURN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-69-45-41(65)34(58)26(57)21-68-45)24-11-16-52(7)33(24)25(56)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)36(60)28(20-55)71-48)74-46-42(66)38(62)35(59)27(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3
|
| Chemical Name |
2-[4,5-dihydroxy-6-(hydroxymethyl)-2-[[12-hydroxy-4,4,8,10,14-pentamethyl-17-[6-methyl-2-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~92.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9265 mL | 4.6327 mL | 9.2654 mL | |
| 5 mM | 0.1853 mL | 0.9265 mL | 1.8531 mL | |
| 10 mM | 0.0927 mL | 0.4633 mL | 0.9265 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
